Clinical trials: Phase III
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Gastric Cancer
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive…
- Trial name
- RILOMET-2 (NCT02137343)
- Testing
- Rilotumumab, Cisplatin, Capecitabine
- Where
- 25 sites in Japan, South Korea
- Volunteers
- 34 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.
- Trial name
- NAUTIKA1 (NCT04302025)
- Testing
- Alectinib, Entrectinib, Vemurafenib
- Where
- 38 sites in United States
- Volunteers
- 99 people
- Sponsor
- Genentech, Inc.
Pneumococcal Disease
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07660198
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 77 sites in United States, Finland and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pre-Exposure Prophylaxis of HIV Infection
Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth…
- Trial name
- PURPOSE 2 (NCT04925752)
- Testing
- Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN)
- Where
- 93 sites in United States, Argentina and 6 more
- Volunteers
- 3,292 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction
BP101 for Adults With Female Sexual Dysfunction
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD).
- Conditions
- Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Sexual Desire Disorder
- Trial name
- NCT03463707
- Testing
- BP101
- Where
- 20 sites in Russia
- Volunteers
- 205 people
- Sponsor
- Ivix LLX
Healthy
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their babies.
- Trial name
- NCT07160244
- Testing
- Multivalent Group B streptococcus vaccine, Infanrix hexa, Prevenar 20
- Where
- 219 sites in United States, Argentina and 13 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant.
- Trial name
- NCT03449134
- Testing
- Gefapixant
- Where
- 156 sites in United States, Argentina and 15 more
- Volunteers
- 732 people
- Sponsor
- Merck Sharp & Dohme LLC
Hygiene
Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional
Primary Objective: To evaluate the potential of hydratation and renewal of the mucosa, through corneometry measurement and individual questionnaire perception.
- Trial name
- NCT01126606
- Testing
- Dermacid Silver (Lactic acid), Glycerine Vegetal Soap Granado Traditional
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Sanofi
Ovarian Neoplasms
Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
The purpose of this research study is to determine if Telcyta® given in combination with liposomal doxorubicin is more effective than liposomal doxorubicin alone in treating women who have recurrent ovarian epithelial cancer…
- Trial name
- ASSIST-5 (NCT00350948)
- Testing
- Telcyta, Liposomal Doxorubicin
- Where
- 71 sites in United States, Belgium and 2 more
- Volunteers
- 244 people
- Sponsor
- Telik
Von Willebrand Disease
rVWF IN PROPHYLAXIS
The purpose of this phase 3 study is to investigate the efficacy and safety, including immunogenicity, thrombogenicity and hypersensitivity reactions, as well as pharmacokinetics (PK), health related quality of life (HRQoL) and…
- Trial name
- NCT02973087
- Testing
- von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant)
- Where
- 35 sites in United States, Canada and 7 more
- Volunteers
- 29 people
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
- Trial name
- NCT06153693
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 184 sites in United States, Australia and 11 more
- Volunteers
- 1,083 people
- Sponsor
- Mineralys Therapeutics Inc.
Metastatic Castration-resistant Prostate Cancer
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- Trial name
- NCT06691984
- Testing
- Xaluritamig, Abiraterone, Enzalutamide
- Where
- 164 sites in United States, Australia and 20 more
- Volunteers
- 707 people
- Sponsor
- Amgen
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Iron Deficiency Anemia
A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
The purpose of the study is to evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared to IV iron sucrose for the treatment of iron deficiency anemia (IDA).
- Trial name
- NCT01114204
- Testing
- Ferumoxytol, Iron Sucrose
- Where
- 96 sites in Australia, France and 12 more
- Volunteers
- 605 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
NSCLC
Iressa as Second Line Therapy in Advanced NSCLC-Asia
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The total number of patients expected to be exposed to study procedures is approximately 150 patients will be recruited by investigational…
- Trial name
- ISTANA (NCT00478049)
- Testing
- Gefitinib, Docetaxel
- Where
- 4 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
- Trial name
- KRYSTAL-12 (NCT04685135)
- Testing
- MRTX849, Docetaxel
- Where
- 380 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Mirati Therapeutics Inc.